You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

pazopanib

( pa-ZO-pa-nib )
Funding:
Exceptional Access Program
  • pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Other Name(s): Votrient®
Appearance: tablet

You might also be interested in